Hepion Pharmaceuticals, Inc. (HEPA): Price and Financial Metrics
GET POWR RATINGS... FREE!
HEPA Stock Price Chart Interactive Chart >
HEPA Price/Volume Stats
| Current price | $0.77 | 52-week high | $2.32 |
| Prev. close | $0.72 | 52-week low | $0.61 |
| Day low | $0.73 | Volume | 268,700 |
| Day high | $0.80 | Avg. volume | 354,728 |
| 50-day MA | $0.97 | Dividend yield | N/A |
| 200-day MA | $1.23 | Market Cap | 58.36M |
Hepion Pharmaceuticals, Inc. (HEPA) Company Bio
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and Tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Latest HEPA News From Around the Web
Below are the latest news stories about Hepion Pharmaceuticals Inc that investors may wish to consider to help them evaluate HEPA as an investment opportunity.
Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH1:07 - Overview of Hepion and NASH 5:51- How Rencofilstat (CRV431) targets NASH 11:08 - When will Rencofilstat be available to the public? 14:57 - Implications of Hepion’s fast track FDA designation 19:21 - Rencofilstat’s ability to treat cancer 26:00 - Biotech stocks in 2022... |
Hepion Pharmaceuticals Appoints World-Renowned Hepatologist, Dr. Eddie C. Cheung, to Lead the Company’s Strategic Medical Affairs in Asia- Dr. Cheung, who has dedicated his career to NASH, hepatocellular carcinoma, fatty liver disease, and viral hepatitis will endeavor to advance Hepion’s business development and partnering efforts in Asia - EDISON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular c |
Hepion Pharmaceuticals to Present at BIO CEO & Investor ConferenceEDISON, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), announced today that its CEO, Dr. Robert Foster, will present a corporate overview at the BIO CEO & Investor Conference on Tuesday, Feburary 15, 2022 at 11:15 a.m. Eastern Time at the New Y |
Hepion''s Rencofilstat Combo Shows Anti-Tumor Activity In Nonclinical Liver Cancer StudyHepion Pharmaceuticals Inc (NASDAQ: HEPA ) has announced the results of a nonclinical research study showing rencofilstat (CRV431) decreased liver tumor growth and extended mouse survival when combined with an anti-PD1 antibody. The effects were observed in fatty livers, suggesting that rencofilstat may increase the treatment potential of anti-PD1 treatment in human liver Full story available on Benzinga.com |
Hepion Pharmaceuticals’ Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer StudyAnti-tumor activity observed in fatty livers suggests rencofilstat may increase the treatment potential of anti-PD1 treatment in human liver cancerEDISON, N.J., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), today announced the results of a nonclinic |
HEPA Price Returns
| 1-mo | -18.94% |
| 3-mo | -25.24% |
| 6-mo | -36.89% |
| 1-year | -54.71% |
| 3-year | -91.01% |
| 5-year | -99.79% |
| YTD | -32.46% |
| 2021 | -47.95% |
| 2020 | -59.14% |
| 2019 | -72.65% |
| 2018 | -90.28% |
| 2017 | -70.00% |
Loading social stream, please wait...